[Characterization of the size variants of a recombinant humanized monoclonal antibody (rhumAb1)].

药学学报 Pub Date : 2016-12-01
Jian Zhao, Wu Zhen-hua, Ming Lü, Zhi-dan Wu, Xiao Liu, Hong-hong Guo, Jin Chen, Xin-qiu Yuan, Li Chen, Bei-fen Shen, Bo-yan Zhang
{"title":"[Characterization of the size variants of a recombinant humanized monoclonal antibody (rhumAb1)].","authors":"Jian Zhao,&nbsp;Wu Zhen-hua,&nbsp;Ming Lü,&nbsp;Zhi-dan Wu,&nbsp;Xiao Liu,&nbsp;Hong-hong Guo,&nbsp;Jin Chen,&nbsp;Xin-qiu Yuan,&nbsp;Li Chen,&nbsp;Bei-fen Shen,&nbsp;Bo-yan Zhang","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The composition and potency of the high temperature (40 ℃) stress induced size variants of a recombinant humanized monoclonal antibody(rhumAb1) were characterized by means of SEC-HPLC, non- reduced CE-SDS, liquid chromatography coupled with mass spectrometry (LC-MS) and antibody dependent cell-mediated cytotoxicity (ADCC) assay. The molecular masses of the four size variants (SEC-1-SEC-4) separated by SEC-HPLC and seven size variants(NR-1-NR-7) detected by non-reduced CE-SDS were all characterized by LC-MS. The major low molecular weight variants were generated due to the hinge region fragmentation of heavy chain. The hinge region cleavage was found mainly in the Ser221-Cys-Asp-Lys-Thr- His-Thr-Cys228 sequence, in which C222-D223 and H226-T227 were the major cleavage sites. The size variants of rhumAb1, namely dimer and fragments, have significantly reduced ADCC activity in comparison with the intact rhumAb1 drug product. This study provided insights into the stability profiling for rhumAb1 drug product. The study protocols presented here may be applicable to the analytical characterization of other monoclonal antibody-based therapeutic products.</p>","PeriodicalId":35924,"journal":{"name":"药学学报","volume":"51 12","pages":"1897-905"},"PeriodicalIF":0.0000,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"药学学报","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The composition and potency of the high temperature (40 ℃) stress induced size variants of a recombinant humanized monoclonal antibody(rhumAb1) were characterized by means of SEC-HPLC, non- reduced CE-SDS, liquid chromatography coupled with mass spectrometry (LC-MS) and antibody dependent cell-mediated cytotoxicity (ADCC) assay. The molecular masses of the four size variants (SEC-1-SEC-4) separated by SEC-HPLC and seven size variants(NR-1-NR-7) detected by non-reduced CE-SDS were all characterized by LC-MS. The major low molecular weight variants were generated due to the hinge region fragmentation of heavy chain. The hinge region cleavage was found mainly in the Ser221-Cys-Asp-Lys-Thr- His-Thr-Cys228 sequence, in which C222-D223 and H226-T227 were the major cleavage sites. The size variants of rhumAb1, namely dimer and fragments, have significantly reduced ADCC activity in comparison with the intact rhumAb1 drug product. This study provided insights into the stability profiling for rhumAb1 drug product. The study protocols presented here may be applicable to the analytical characterization of other monoclonal antibody-based therapeutic products.

[重组人源化单克隆抗体(rhumAb1)大小变异的表征]。
采用SEC-HPLC、非还原CE-SDS、液相色谱-质谱联用(LC-MS)和抗体依赖的细胞介导细胞毒性(ADCC)试验对重组人源化单克隆抗体(rhumAb1)高温(40℃)诱导大小变异的组成和效价进行了表征。用SEC-HPLC分离的4个大小变异(SEC-1-SEC-4)和非还原CE-SDS检测的7个大小变异(NR-1-NR-7)的分子质量均用LC-MS表征。主要的低分子量变异是由于重链铰链区断裂而产生的。铰链区断裂主要发生在Ser221-Cys-Asp-Lys-Thr- His-Thr-Cys228序列,其中C222-D223和H226-T227是主要的断裂位点。rhumAb1的大小变异,即二聚体和片段,与完整的rhumAb1药物制品相比,显著降低了ADCC活性。本研究为rhumAb1制剂的稳定性分析提供了新的思路。本文提出的研究方案可能适用于其他以单克隆抗体为基础的治疗产品的分析表征。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
药学学报
药学学报 Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
1.20
自引率
0.00%
发文量
0
期刊介绍: Acta Pharmaceutica Sinica B (APSB) is a bimonthly English peer-reviewed online journal in ScienceDirect, which publishes significant original research articles, communications and high quality reviews of recent advances. APSB encourages submissions from all areas of pharmaceutical sciences, including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics. APSB is a part of the series Acta Pharmaceutica Sinica, which was founded in 1953. The journal is co-published by Elsevier B.V., in association with the Institute of MateriaMedica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信